Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition

참고문헌 (79)

1. Nishiyama, A., "Navigating the DNA methylation landscape of cancer", Trends Genet, 37, pp.1012~1027 (2021)
2. Parry, A., "Active turnover of DNA methylation during cell fate decisions", Nat. Rev. Genet, 22, pp.59~66 (2021)
3. Mahmood, N., "DNA methylation readers and cancer : mechanistic and therapeutic applications", Front. Oncol, 9, pp.489~ (2019)
4. Greenberg, M. V., "The diverse roles of DNA methylation in mammalian development and disease", Nat. Rev. Mol. Cell Biol, 20, pp.590~607 (2019)
5. Hanahan, D., "Hallmarks of cancer : new dimensions", Cancer Discov, 12, pp.31~46 (2022)
6. Silverman, L. R., "Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome : a study of the cancer and leukemia group B", J. Clin. Oncol, 20, pp.2429~2440 (2002)
7. Cheishvili, D., "DNA demethylation and invasive cancer : implications for therapeutics", Br. J. Pharmacol, 172, pp.2705~2715 (2015)
8. Jones, P. A., "Targeting the cancer epigenome for therapy", Nat. Rev. Genet, 17, pp.630~ (2016)
9. Ateeq, B., "Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo", Neoplasia(N. Y., N. Y. ), 10, pp.266~278 (2008)
10. Fraga, M. F., "The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties", Nucleic acids Res, 31, pp.1765~1774 (2003)
11. Hendrich, B., "Closely related pro teins MBD2 and MBD3 play distinctive but interacting roles in mouse", Dev. Genes Dev, 15, pp.710~723 (2001)
12. Sansom, O. J., "Deficiency of Mbd2 suppresses intestinal tumorigenesis", Nat. Genet, 34, pp.145~147 (2003)
13. Zhou, M., "MBD2 ablation impairs lymphopoiesis and impedes progression and maintenance of T-ALL", Cancer Res, 78, pp.1632~1642 (2018)
14. Campbell, P. M., "Methylated DNA-binding protein 2 anti sense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo", Carcinogenesis, 25, pp.499~507 (2004)
15. Liu, Z., "Hypoxia-Induced Suppression of Alternative Splicing of MBD2 Pro motes Breast Cancer Metastasis via Activation of FZD1Suppression of MBD2Splicing Promotes Breast Cancer Metastasis", Cancer Res, 81, pp.1265~1278 (2021)
16. Mian, O. Y., "Methyl-binding domain protein 2–dependent proliferation and survival of breast cancer cells", Mol. Cancer Res, 9, pp.1152~1162 (2011)
17. Cheishvili, D., "Synergistic effects of combined DNA methyltransferase inhi bition and MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza 2ʹ-deoxycytidine-triggered invasiveness", Carcinogenesis, 35, pp.2436~2446 (2014)
18. Day, C. -P., "Preclinical mouse cancer models : a maze of opportunities and challenges", Cell, 163, pp.39~53 (2015)
19. Guy, C. T., "Induction of mammary tumors by expression of polyomavirus middle T oncogene : a transgenic mouse model for metastatic disease", Mol. Cell. Biol, 12, pp.954~961 (1992)
20. Fantozzi, A., "Mouse models of breast cancer metastasis", Breast Cancer Res, 8, pp.212~ (2006)
21. Lin, E. Y., "Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases", Am. J. Pathol, 163, pp.2113~2126 (2003)
22. Fluck, M. M., "Lessons in signaling and tumorigenesis from polyomavirus middle T antigen", Microbiol. Mol. Biol. Rev, 73, pp.542~563 (2009)
23. Mahmood, N., "uPAR antibody(huATN-658)and Zometa reduce breast cancer growth and skeletal lesions", Bone Res, 8, pp.1~12 (2020)
24. Livak, K. J., "Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T))Method", Methods(San. Diego, Calif. ), 25, pp.402~408 (2001)
25. Langmead, B., "Fast gapped-read alignment with Bowtie 2", Nat. methods, 9, pp.357~ (2012)
26. Zhang, Y., "Model-based analysis of ChIP-Seq(MACS)", Genome Biol, 9, pp.1~9 (2008)
27. Heinz, S., "Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities", Mol. cell, 38, pp.576~589 (2010)
28. Kamburov, A., "The ConsensusPathDB interac tion database : 2013 update", Nucleic acids Res, 41, pp.D793~D800 (2013)
29. Kim, D., "HISAT : a fast spliced aligner with low memory requirements", Nat. methods, 12, pp.357~360 (2015)
30. Pertea, M., "StringTie enables improved reconstruction of a transcriptome from RNA-seq reads", Nat. Biotechnol, 33, pp.290~295 (2015)
31. Robinson, M. D., "edgeR : a Bioconductor package for differential expression analysis of digital gene expression data", bioinformatics, 26, pp.139~140 (2010)
32. Kong, L., "CPC : assess the protein-coding potential of transcripts using sequence features and support vector machine", Nucleic acids Res, 35, pp.W345~W349 (2007)
33. Sun, L., "Utilizing sequence intrinsic composition to classify protein-coding and long non-coding transcripts", Nucleic acids Res, 41, pp.e166~e166 (2013)
34. Searle, B. C., "Scaffold : a bioinformatic tool for validating MS", MS-based proteomic studies, 2010, pp.10, 1265~1269
35. Tuominen, V. J., "ImmunoRatio : a publicly available web application for quantitative image analysis of estrogen receptor(ER), progesterone receptor(PR), and Ki-67", Breast cancer Res. : BCR, 12, pp.R56~R56 (2010)
36. Mahmood, N., "Methyl donor S-adenosylmethionine(SAM)supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications", Oncotarget, 9, pp.5169~5183 (2018)
37. Chandrashekar, D. S., "UALCAN : An update to the integrated cancer data analysis platform", Neoplasia, 25, pp.18~27 (2022)
38. Cheng, L., "Deletion of MBD2 inhibits proliferation of chronic myeloid leu kaemia blast phase cells", Cancer Biol. Ther, 19, pp.676~686 (2018)
39. Kim, M. Y., "Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2", Sci. Adv, 5, pp.eaav9810~ (2019)
40. Liu, Z., "Hypoxia-induced suppression of alternative splicing of MBD2 promotes breast cancer metastasis via activation of FZD1", Cancer Res, 81, pp.1265~1278 (2021)
41. Lax, E., "Methyl-CpG binding domain 2(Mbd2)is an epigenetic regulator of autism-risk genes and cognition", Transl. Psychiatry, 13, pp.259~ (2023)
42. Zou, Z., "ChIP-Atlas 2021 update : a data-mining suite for exploring epigenomic landscapes by fully integrating ChIP-seq, ATAC-seq and Bisulfite-seq data", Nucleic Acids Res, 1, pp.175~182 (2022)
43. Zhou, Y., "Metascape provides a biologist-oriented resource for the analysis of systems-level datasets", Nat. Commun, 10, pp.1523~ (2019)
44. Hondermarck, H., "Neurotrophins and their receptors in breast cancer", Cytokine Growth Factor Rev, 23, pp.357~365 (2012)
45. Ueda, K., "Dual-specificity phosphatase 5(DUSP5)as a direct transcriptional target of tumor suppressor p53", Oncogene, 22, pp.5586~5591 (2003)
46. Li, N., "Forkhead-box A3 (FOXA3) represses cancer stemness and partially potentiates chemosensitivity by targeting metastasis-associated in colon cancer 1 (MACC1) signaling pathway in colorectal cancer cells", Curr Cancer Drug Targets (2020)[DOI]
47. Kurz, S., "The anti-tumorigenic activity of A2M-A lesson from the naked mole rat", PLoS One, 12, pp.e0189514~ (2017)
48. Dang, T. T., "ΔNp63α induces the expression of FAT2 and Slug to promote tumor invasion", Oncotarget, 7, pp.28592~28611 (2016)
49. Zoppino, F. C. M., "Com prehensive transcriptomic analysis of heat shock proteins in the molecular sub types of human breast cancer", BMC Cancer, 18, pp.700~ (2018)
50. Stefansson, O. A., "BRCA1 as a tumor suppressor linked to the reg ulation of epigenetic states : keeping oncomiRs under control", Breast Cancer Res, 14, pp.304~ (2012)
51. Djebali, S., "Landscape of transcription in human cells", Nature, 489, pp.101~108 (2012)
52. Barr, H., "Mbd2 contributes to DNA methylation-directed repression of the Xist gene", Mol. Cell Biol, 27, pp.3750~3757 (2007)
53. Phesse, T. J., "Deficiency of Mbd2 attenuates Wnt signaling", Mol. Cell Biol, 28, pp.6094~6103 (2008)
54. He, T. -C., "Identification of c-MYC as a target of the APC pathway", Science, 281, pp.1509~1512 (1998)
55. Zhao, M., "dbEMT 2.0: An updated database for epithelial-mesenchymal transition genes with experimentally verified informa tion and precalculated regulation information for cancer metastasis", J. Genet Genomics, 46, pp.595~597 (2019)
56. Loh, C. Y., "The E-Cadherin and N-Cadherin Switch in Epithelial-to Mesenchymal Transition : Signaling, Therapeutic Implications, and Challenges", Cells, 8 (2019)[DOI]
57. Jing, Y., "SPARC promotes the proliferation and metastasis of oral squamous cell carcinoma by PI3K", AKT, PDGFRβ axis, pp.J. Cell. Physiol, 2019[DOI]
58. Deng, S., "Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarci noma cells", Tissue Cell, 76, pp.101756~ (2022)
59. Hao, C., "OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase", Sci. Rep, 9, pp.1~14 (2019)
60. Le Naour, A., "EO771, the first luminal B mammary cancer cell line from C57BL", 6 mice, 2020, pp.20, 1~13
61. Mahmood, N., "S-adeno sylmethionine in combination with decitabine shows enhanced anti-cancer effects in repressing breast cancer growth and metastasis", J. Cell. Mol. Med, 24, pp.10322~10337 (2020)
62. Shang, S., "MBD2a–NuRD binds to the methylated γ-globin gene promoter and uniquely forms a complex required for silencing of HbF expression", Proc. Natl Acad. Sci, 120, pp.e2302254120~ (2023)
63. Croci, D. O., "Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment", Cancer Immunol., Immunother, 56, pp.1687~1700 (2007)
64. Wood, K. H., "Emerging molecular and biological functions of MBD2, a reader of DNA methylation", Front. Genet, 7, pp.93~ (2016)
65. Wang, L., "Mbd2 promotes foxp3 demethylation and T-regulatory-cell func tion", Mol. Cell Biol, 33, pp.4106~4115 (2013)
66. Wang, Y., "MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program", Sci. Adv, 7, pp.eabb6075~ (2021)
67. Wang, Y., "The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation", Eur. Resp. J, 60, pp.2003697~ (2022)
68. Millet, C., "Roles of Smad3 in TGF-beta signaling during carcino genesis", Crit. Rev. Eukaryot. Gene Expr, 17, pp.281~293 (2007)
69. Zhang, Y., "Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation", Genes Dev, 13, pp.1924~1935 (1999)
70. Devailly, G., "Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells", Nucleic Acids Res (2015)[DOI]
71. Baubec, T., "Methylation-Dependent and-Independent Genomic Targeting Principles of the MBD Protein Family", Cell, 153, pp.480~492 (2013)
72. Stefanska, B., "Definition of the landscape of promoter DNA hypomethylation in liver cancer", Cancer Res (2011)
73. Stefanska, B., "Transcription onset of genes critical in liver carcinogenesis is epigenetically regulated by methylated DNA-binding protein MBD2", Carcino genesis, 34, pp.2738~2749 (2013)
74. Roche, J., (2018), Multidisciplinary Digital Publishing Institute
75. Zhang, L., "MBD2 facilitates tumor metastasis by mitigating DDB2 expression", Cell Death Dis, 14, pp.303~ (2023)
76. Sangaletti, S., "Osteopontin shapes immunosuppression in the metastatic niche", Cancer Res, 74, pp.4706~4719 (2014)
77. Sangaletti, S., "SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities", Front Immunol, 10, pp.1369~ (2019)
78. Dongre, A., "The role of the EMT program in reg ulating the immune response in carcinoma", Front. Immunol, 13, pp.940164~ (2022)
79. Zhu, D., "BAI1 Suppresses Medulloblastoma Formation by Protecting p53from Mdm2-Mediated Degradation", Cancer Cell, 33, pp.1004~1016 (2018)

관련 논문AI추천